Whois & Analysis for orilissa.com

Endometriosis is a condition in which tissue that normally grows inside the uterus (endometrium) grows outside it.

Most often this is on the ovaries, fallopian tubes, and tissue around the uterus and ovaries; however, in rare cases it may also occur in other parts of the body.

The main symptoms are pelvic pain and infertility.

Nearly half of those affected have chronic pelvic pain, while in 70% pain occurs during menstruation.

Pain during sex is also common.

Infertility occurs in up to half of women affected.

Less common symptoms include urinary or bowel symptoms.

About 25% of women have no symptoms.

Endometriosis can have both social and psychological effects.

Dyspareunia is painful sexual intercourse due to medical or psychological causes.

The pain can primarily be on the external surface of the genitalia, or deeper in the pelvis upon deep pressure against the cervix.

It can affect a small portion of the vulva or vagina or be felt all over the surface.

Understanding the duration, location, and nature of the pain is important in identifying the causes of the pain.

Elagolix (INN, USAN) (former developmental code names NBI-56418, ABT-620) is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM) that is under development for clinical use by Neurocrine Biosciences and AbbVie.

As of 2015, it is in phase III clinical trials for the treatment of endometriosis and uterine leiomyoma.

The drug was also under investigation for the treatment of prostate cancer and benign prostatic hyperplasia, but development for these indications was ultimately not pursued.

Elagolix is the first of a new class of GnRH inhibitors that have been denoted as second-generation, due to their non-peptide nature and oral bioavailability.

A placebo (Latin , "I shall please" from , "I please") is a substance or treatment with no active therapeutic effect.

A placebo may be given to a person in order to deceive the recipient into thinking that it is an active treatment.

In drug testing and medical research, a placebo can be made to resemble an active medication or therapy so that it functions as a control; this is to prevent the recipient(s) and/or others from knowing (with their consent) whether a treatment is active or inactive, as expectations about efficacy can influence results.

This phenomenon, in which the recipient perceives an improvement in condition due to personal expectations, rather than the treatment itself, is known as the placebo effect or placebo response.

Research about the effect is ongoing.

Dysmenorrhea, also known as dysmenorrhoea, painful periods, or menstrual cramps, is pain during menstruation.

It usually begins around the time that menstruation begins.

Symptoms typically last less than three days.

The pain is usually in the pelvis or lower abdomen.

Other symptoms may include back pain, diarrhea, or nausea.